Literature DB >> 23685547

Response of neurotensin basal ganglia systems during extinction of methamphetamine self-administration in rat.

Glen R Hanson1, Amanda J Hoonakker, Christina M Robson, Lisa M McFadden, Paul S Frankel, Mario E Alburges.   

Abstract

Because of persistent social problems caused by methamphetamine (METH), new therapeutic strategies need to be developed. Thus, we investigated the response of central nervous system neurotensin (NT) systems to METH self-administration (SA) and their interaction with basal ganglia dopamine (DA) pathways. Neurotensin is a peptide associated with inhibitory feedback pathways to nigrostriatal DA projections. We observed that NT levels decreased in rats during extinction of METH SA when lever pressing resulted in intravenous infusions of saline rather than METH. Thus, 6 h after the first session of extinction, NT levels were 53, 42, and 49% of corresponding controls in the anterior dorsal striatum, posterior dorsal striatum, and globus pallidus, respectively. NT levels were also significantly reduced in corresponding yoked rats in the anterior dorsal striatum (64% of control), but not the other structures examined. The reductions in NT levels in the anterior dorsal striatum particularly correlated with the lever pressing during the first session of extinction (r =s; 0.745). These, and previously reported findings, suggest that the extinction-related reductions in NT levels were mediated by activation of D2 receptors. Finally, administration of the neurotensin receptor 1 (NTR1) agonist [PD149163 [Lys(CH2NH)Lys-Pro,Trp-tert-Leu-Leu-Oet]; 0.25 or 0.5 mg/kg] diminished lever pressing during the first extinction session, whereas the NTR1 antagonist [SR48692 [2-[(1-(7-chloro-4-quinolinyl)-5-(2,6-imethoxyphenyl)pyrazol-3-yl)carbonylamino]tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid]; 0.3 mg/kg per administration] attenuated the reduction of lever pressing during the second to fourth days of extinction. In summary, these findings support the hypothesis that some of the endogenous basal ganglia NT systems contribute to the elimination of contingent behavior during the early stages of the METH SA extinction process.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23685547      PMCID: PMC3716310          DOI: 10.1124/jpet.113.205310

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

Review 1.  Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms.

Authors:  G R Hanson; N Singh; K Merchant; M Johnson; L Bush; J W Gibb
Journal:  Ann N Y Acad Sci       Date:  1992       Impact factor: 5.691

2.  Molecular cloning and expression of the gene for a human D1 dopamine receptor.

Authors:  A Dearry; J A Gingrich; P Falardeau; R T Fremeau; M D Bates; M G Caron
Journal:  Nature       Date:  1990-09-06       Impact factor: 49.962

3.  Dopamine D2 receptors exert tonic regulation over discrete neurotensin systems of the rat brain.

Authors:  K M Merchant; L G Bush; J W Gibb; G R Hanson
Journal:  Brain Res       Date:  1989-10-23       Impact factor: 3.252

4.  Response by the neurotensin systems of the basal ganglia to cocaine treatment.

Authors:  G R Hanson; P Smiley; M Johnson; A Letter; L Bush; J W Gibb
Journal:  Eur J Pharmacol       Date:  1989-01-24       Impact factor: 4.432

5.  D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

Authors:  C R Gerfen; T M Engber; L C Mahan; Z Susel; T N Chase; F J Monsma; D R Sibley
Journal:  Science       Date:  1990-12-07       Impact factor: 47.728

6.  Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: comparison with acute haloperidol effects.

Authors:  K M Merchant; G R Hanson; D M Dorsa
Journal:  J Pharmacol Exp Ther       Date:  1994-05       Impact factor: 4.030

7.  Immunohistochemical evidence for a neurotensin striatonigral pathway in the rat brain.

Authors:  M N Castel; P Morino; P Frey; L Terenius; T Hökfelt
Journal:  Neuroscience       Date:  1993-08       Impact factor: 3.590

8.  Differential dopaminergic regulation of the neurotensin striatonigral and striatopallidal pathways in the rat.

Authors:  M N Castel; P Morino; I Nylander; L Terenius; T Hökfelt
Journal:  Eur J Pharmacol       Date:  1994-09-01       Impact factor: 4.432

9.  Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment.

Authors:  M N Castel; P Morino; A Dagerlind; T Hökfelt
Journal:  Eur J Neurosci       Date:  1994-04-01       Impact factor: 3.386

10.  Effect of methamphetamine on neurotensin concentrations in rat brain regions.

Authors:  A A Letter; K Merchant; J W Gibb; G R Hanson
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030

View more
  13 in total

1.  Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Paula L Vieira-Brock; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2015-01-31       Impact factor: 5.250

2.  Diverse actions of the modulatory peptide neurotensin on central synaptic transmission.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Eur J Neurosci       Date:  2018-02-28       Impact factor: 3.386

3.  Neurotensin speeds inhibition of dopamine neurons through temporal modulation of GABAA and GABAB receptor-mediated synaptic input.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Neuropharmacology       Date:  2018-01-05       Impact factor: 5.250

4.  Effect of low doses of methamphetamine on rat limbic-related neurotensin systems.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Synapse       Date:  2015-06-11       Impact factor: 2.562

Review 5.  Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

Authors:  Christopher L German; Michelle G Baladi; Lisa M McFadden; Glen R Hanson; Annette E Fleckenstein
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

6.  Responses of the rat basal ganglia neurotensin systems to low doses of methamphetamine.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

7.  ML314: A Biased Neurotensin Receptor Ligand for Methamphetamine Abuse.

Authors:  Larry S Barak; Yushi Bai; Sean Peterson; Tama Evron; Nikhil M Urs; Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick R Maloney; Thomas D Y Chung; Ramona M Rodriguiz; William C Wetsel; James B Thomas; Glen R Hanson; Anthony B Pinkerton; Marc G Caron
Journal:  ACS Chem Biol       Date:  2016-05-05       Impact factor: 5.100

8.  A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties.

Authors:  Hee-Kyoung Lee; Liuyin Zhang; Misty D Smith; Aleksandra Walewska; Nadeem A Vellore; Riccardo Baron; J Michael McIntosh; H Steve White; Baldomero M Olivera; Grzegorz Bulaj
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

9.  Genome-wide profiling identifies a subset of methamphetamine (METH)-induced genes associated with METH-induced increased H4K5Ac binding in the rat striatum.

Authors:  Jean Lud Cadet; Subramaniam Jayanthi; Michael T McCoy; Bruce Ladenheim; Fabienne Saint-Preux; Elin Lehrmann; Supriyo De; Kevin G Becker; Christie Brannock
Journal:  BMC Genomics       Date:  2013-08-12       Impact factor: 3.969

10.  Neurotensin receptor 1 deletion decreases methamphetamine self-administration and the associated reduction in dopamine cell firing.

Authors:  Sergio Dominguez-Lopez; Ramaswamy Sharma; Michael J Beckstead
Journal:  Addict Biol       Date:  2019-11-19       Impact factor: 4.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.